Avanos Medical Inc.
AVNS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AVNS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AVNS
Avanos Medical Inc. is a medical device company focused on digestive health and pain management, having divested its respiratory health business to streamline operations and reduce opioid use.
Key risk: Pricing and cost-containment pressures
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Mar 31, 2026.
Avanos Medical Inc. is a medical device company focused on digestive health and pain management, having divested its respiratory health business to streamline operations and reduce opioid use.
- Completed divestiture of its respiratory health (RH) business as part of a transformation initiative to focus on core product portfolio [sec · filed 2025-03-14].
- Reported cash & equivalents of $65.6M, total revenue of $182.2M, net income of $5.1M, shareholders' equity of $778.2M, and total debt of $98.2M as of 2026-03-31 [sec].
- Anticipates gross savings of approximately $50 million from transformation initiatives compared to 2022 baseline [sec · filed 2025-03-14].
- Committed to reducing opioid use and providing nutrition solutions from hospital to home [sec_mda · as of 2025-08-05].
What works
- Completed divestiture of respiratory health business, sharpening focus on higher-growth digestive health and pain management categories [sec · filed 2025-03-14].
- Expects approximately $50 million in gross savings from transformation initiatives, which may improve operating profitability [sec · filed 2025-03-14].
- Holds leading market positions in multiple product categories globally [sec_mda · as of 2025-08-05].
What to weigh
- Exposed to pricing pressures and cost-containment measures that could adversely affect product demand or pricing [sec_mda · as of 2026-05-05].
- Transformation and restructuring activities involve execution risks and may not achieve expected benefits [sec_mda · as of 2026-05-05].
- General economic conditions, particularly in the United States, could weaken demand for products [sec_mda · as of 2026-05-05].
From the filings
Quoted directly from source documents.
Company completed divestiture of respiratory health business as part of transformation
“divestiture of our respiratory health ("RH") business”
SEC filings · March 14, 2025
Anticipated gross savings of approximately $50 million from transformation
“the Company anticipates that the transformation initiative will ultimately result in gross savings of approximately $50 million compared to 2”
SEC filings · March 14, 2025
Company holds leading market positions globally
“hold leading market positions in multiple categories across our portfolio”
SEC MD&A · August 5, 2025
Pricing pressures could adversely affect demand or pricing
“pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products”
SEC filings · May 5, 2026
Risks & what to watch (4)›
Key risks
- Pricing and cost-containment pressures — Pricing pressures and cost-containment measures could reduce demand or pricing for products [sec_mda · as of 2026-05-05].
- Transformation execution risk — Restructuring and transformation initiatives may not achieve expected savings or benefits [sec_mda · as of 2026-05-05].
- Economic downturn impact — Weakening economic conditions, particularly in the U.S., could lower demand for products [sec_mda · as of 2026-05-05].
- Regulatory and legal risks — Legislative actions, product liability claims, and compliance risks could impact operations [sec · filed 2018-06-01].
What to watch
- Progress on transformation savings target of $50 million and any updates on cost management initiatives [sec · filed 2025-03-14].
- Organic growth performance in Pain Management & Recovery (excluding HA products) as a key strategic metric [sec · filed 2025-03-14].
- Ability to maintain operating cash flow and liquidity to fund working capital and capital expenditures [sec_mda · as of 2026-05-05].
- Any acquisition or capital allocation moves that meet strategic and financial criteria [sec · filed 2025-03-14].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Avanos Medical Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Avanos Medical Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
35.0 months
D/E 0.34 · 2% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
255
Total value held
$544.4M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 6,843,733 | $95.9M |
| vanguard capital management llc | 3,943,930 | $55.3M |
| brown advisory inc | 2,231,198 | $31.3M |
| dimensional fund advisors lp | 2,052,356 | $28.8M |
| armistice capital, llc | 2,000,000 | $28.0M |
| state street corp | 1,972,523 | $27.6M |
| vanguard portfolio management llc | 1,239,295 | $17.4M |
| boone capital management llc | 1,184,909 | $16.6M |
| geode capital management, llc | 1,094,235 | $15.3M |
| charles schwab investment management inc | 1,058,066 | $14.8M |
Showing top 10 of 255 institutional holders of Avanos Medical Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 3.5%
- Days to cover
- 0.6
- Shares short
- 1,211,005
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AVNS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Avanos Medical Inc.?
Avanos Medical Inc. is a medical device company focused on digestive health and pain management, having divested its respiratory health business to streamline operations and reduce opioid use.
Who is the CEO of Avanos Medical Inc.?
Mr. David C. Pacitti M.B.A. is the chief executive officer of Avanos Medical Inc. (AVNS).
Where is Avanos Medical Inc. headquartered?
Avanos Medical Inc. (AVNS) is headquartered in Alpharetta, GA, United States.
What therapeutic areas does Avanos Medical Inc. focus on?
Avanos Medical Inc. develops therapies across Pain, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.